Colony-stimulating factors (CSFs) are glycoproteins that stimulate the growth of hematopoietic progenitors and enhance the functional activity of mature effector cells.
Hematopoietic progenitor cells give rise to colonies of differentiated cells in semisolid medium in the presence of colony-stimulating factors (CSFs) (1) . CSFs also affect the function of mature peripheral effector cells, and previous studies (2, 3) have implicated CSFs to be primary regulators of granulopoiesis. The biological and molecular properties of several human and murine CSFs have been characterized (reviewed in refs. 4 and 5) . Human granulocyte/macrophage colony-stimulating factor (GM-CSF) is a 22-kDa glycoprotein originally purified from medium conditioned by the human T-cell leukemia virus type II (HTLV-II)-infected Tlymphoblast cell line Mo (6) . cDNA clones encoding functional protein have been isolated (7) . Both purified natural and biosynthetic (recombinant) GM-CSF stimulate the formation of granulocyte, macrophage, granulocyte/macrophage, and eosinophil colonies, as well as erythroid bursts from normal progenitors in vitro (8) (9) (10) . Colony formation by the human myeloid leukemic cell lines HL-60 and KG-1 is also increased by GM-CSF (8) . Like other CSFs, GM-CSF has direct actions on peripheral blood neutrophils; it enhances chemotaxis, phagocytosis, and superoxide production in response to physiologic stimuli such as N-formylmethionylleucylphenylalanine and the complement derivative C5a (6, (11) (12) (13) . In addition, GM-CSF enhances antibody-mediated killing of Schistosoma larvae by human eosinophils in vitro (14) . The gene encoding GM-CSF is 2.5 kilobases (kb) long, with three intervening sequences, and maps to the long arm of chromosome 5 (15, 16) .
Previous work has shown that GM-CSF is a T-cell-derived growth factor. Phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes produce GM-CSF, as do all HTLV-Ior HTLV-II-infected T-cell lines tested (7, 17) . The basal level of GM-CSF production in the HTLV-infected cell lines can be increased up to 10-fold after PHA and phorbol 12-myristate 13-acetate (PMA) treatment (7) .
In this study, we have investigated the cellular sources of GM-CSF mRNA and protein. We have used a recombinant construction to identify a region of the GM-CSF gene involved in regulating expression in stimulated T-cell lines.
MATERIALS AND METHODS GM-CSF Radioimmunoassay. Antisera were raised against GM-CSF by injection of rabbits with purified biosynthetic protein (=5 gg) in complete Freund's adjuvant at multiple intradermal sites. Rabbits were given booster injections at monthly intervals with the same protein in incomplete Freund's adjuvant and were bled from the ear vein 10 days after each injection. Antisera were titrated using 25,000-30,000 cpm of 1251-labeled (chloramine-T method) GM-CSF per tube, and antigen-antibody complexes were precipitated with fixed Staphylococcus aureus cells. The dilution of antiserum that precipitated 10,000-15,000 cpm of 1251-labeled GM-CSF was used in the radioimmunoassay. The GM-CSF standard was purified biosynthetic human GM-CSF produced by transfection of monkey COS cells, as described (6, 7) . The concentration of the standard was estimated by amino acid analysis. Multiple dilutions of samples were assayed in 0.2 ml (final volume) of Dulbecco's phosphate-buffered saline (Ca2+-and Mg2+-free) containing 0.2% Nonidet P-40, 0.2 mg of bovine serum albumin, 0.1 mM phenylmethylsulfonyl fluoride, 25,000-30,000 cpm of 1251-labeled GM-CSF, the appropriate dilution of antiserum (1:2500 in Table 1) , and carrier rabbit immunoglobulin. After overnight incubation at 4°C, goat anti-rabbit serum was added and incubation was continued for an additional 3 hr. After centrifugation, pelleted radioactivity was measured in a gamma counter, and dilutions of the sample were compared to dilutions of the standard. Previous work (unpublished) has shown that only medium conditioned by cells known to make GM-CSF (as determined by bioassay and RNA hybridization) contains GM-CSF detectable by this radioimmunoassay and that the assay does not detect macrophage CSF or granulocyte CSF.
Construction of Plasmids. Plasmid constructs were prepared by standard procedures. The plasmid pCHPO.8 was derived from the GM-CSF genomic clone pCH5.2 (15 (21) . CAT activity was determined by the acetylation of 14C-labeled chloramphenicol assayed by thin-layer chromatography and autoradiography.
Nuclease S1 Analysis. The transcriptional start site of GM-CSF was determined by nuclease S1 analysis (22, 23) . Probes were end-labeled by bacteriophage T4 polynucleotide kinase to a specific activity of about 107 cpm/,g of DNA. Approximately 0.02 ,ug of the probe was hybridized to 20 ,ug of total cellular RNA in 20 ,ul of 80% deionized formamide plus 5 ,l of 2 M NaCl/200 mM Pipes, pH 6.4/5 mM EDTA, pH 7.0. Hybridization was allowed to proceed at 53°C for 12 hr. After hybridization, the samples were digested with 40 units of nuclease S1 in 250 Al of S1 digestion buffer for 1 hr at 37°C. S1-protected DNA was ethanol-precipitated, electrophoresed in an 8 M urea/10% acrylamide gel, and autoradiographed.
RESULTS
Cell and Tissue Sources of GM-CSF. GM-CSF mRNA is present in activated but not resting T lymphocytes (7) . To determine whether any human tissues constitutively produce GM-CSF, poly(A)+ RNA was prepared as described (24) from various fresh neoplasms and the surrounding normal tissue and screened by dot blot hybridization analysis with the full-length GM-CSF cDNA as a probe. No GM-CSF message was detected in 57 samples including liver, colon, esophagus, rectum, stomach, breast, lung, skin, seminona, neuroblastoma, melanoma, renal, and ovarian carcinomas and surrounding normal tissue. In addition, 7 leukemic cell samples were tested, including acute myelogenous leukemia, acute lymphoblastic leukemia, and acute myelomonocytic leukemia (data not shown). The limit of detection of this method is 40 pg of a specific transcript in 4 ,g of poly(A)+ RNA (24) . The RNA samples were fractionated by electrophoresis in agarose gels in order to substantiate the integrity of the RNAs, and the dot blots were hybridized with an erythroid-potentiating activity (EPA) probe. The EPA probe has been found to be expressed by most human cells (unpublished data), and all the samples showed hybridization to the probe, thus confirming their integrity.
Activated T Cells Produce Increased Levels of GM-CSF.
Previous studies (7), using blot hybridization analysis of electrophoretically fractionated RNA, have shown that HTLV-infected T-lymphoblast cell lines increased the expression of GM-CSF mRNA when treated with PHA/PMA (7) . Nuclease S1 analysis of RNA from the S-LB-I (HTLV-I-infected) cell line was performed, using a fragment derived from the previously isolated GM-CSF genomic clone (15) . The probe was the Hinfl-Dde I fragment from plasmid pCHPO.8, encompassing nucleotides -70 to 196 and containing the first exon and its 5' flanking sequences. The 266-nucleotide fragment was 5'-labeled at the Dde I site. Two bands at =165 bp were protected, and the level of GM-CSF transcript increased =10-fold after 20 hr of treatment of S-LB-I cells with 0.5% PHA and 10 ng of PMA per ml (Fig.  1) . To determine whether the levels of GM-CSF mRNA are reflected in increased protein, we developed a radioimmunoassay to estimate the concentration of GM-CSF protein in conditioned media from stimulated and unstimulated S-LB-I cells. In four separate experiments, the radioimmunoassay detected a 3-to 7-fold increase in GM-CSF Fig. 1) . To define the nucleotide sequences required in cis for expression of GM-CSF in activated T cells, we prepared recombinant constructs of the GM-CSF gene linked to the CAT gene and used the S-LB-I cell line as a model for activated T lymphocytes.
There is much evidence demonstrating the importance of sequences upstream from the cap site in the regulation of transcription (25) . Thus, to include the cap site in the construction of +pCSFPI and -pCSFPI, DNA sequencing [Maxam and Gilbert method (19) ] was performed using the same Hinfl-Dde I probe and analyzed simultaneously with the S1 analysis. The sequencing "ladder" shows the initiation site at nucleotides C and G at positions 1 and 3, respectively (Fig. lb) .
A 660-nucleotide fragment 5' from the initiation codon of the GM-CSF gene and including the cap site (see above) was subcloned into the BUG-CAT plasmid, replacing its SV40 early promoter and nonfunctional immunoglobulin sequence (Fig. 3) . The recombinant construct in the positive orientation (+pCSFPI) and that in the reverse orientation (-pCSFPI) were transfected into S-LB-I cells using a DEAEdextran transfection procedure (see Materials and Methods). The cells were harvested with and without stimulation with PHA/PMA and assayed for CAT enzyme activity. +pCSFPI-transfected cells showed increased CAT levels when stimulated with 0.5% or 1.0% PHA and 10 ng of PMA per ml (Fig. 4) . +pCSFPI-transfected cells also showed an increase in CAT activity when stimulated with PMA alone (data not shown). Nonstimulated +pCSFPI-transfected cells showed CAT activity levels similar to stimulated and non- Medium was harvested at 20 hr from stimulated and control (nonstimulated) cells, and GM-CSF was determined by radioimmunoassay (see Materials and Methods and Fig. 2) . The experiment was repeated four times. Determinations were done once for each experiment. Standard provided internal control.
stimulated -pCSFPI-transfected cells. The overall enhancement in five experiments was =5-fold, as determined by liquid scintillation counting, similar to the increases seen in GM-CSF protein (see Table 1 ).
Previous studies on interleukin 2 (IL-2) expression showed that treatment of T cells with the OKT3 monoclonal antibody and PMA mimics T-cell activation, whereas no IL-2 production was observed when Jurkat cells were cultured with either OKT3 or PMA alone over a wide range of doses (26) . Based on this observation, cells were stimulated with 1:100 and 1:400 dilutions of OKT3 plus 50 ng of PMA per ml. Increased expression of +pCSFPI and not -pCSFPI was observed (Fig. 4) . pSVcat (kindly provided by J. Banerji), containing the SV40 enhancer and promoter, was used as a positive control for transfection efficiency; no increased expression of pSVcat was seen when S-LB-I cells were stimulated with PHA plus PMA or with PMA alone (data not shown). BUG-CAT, containing the SV40 promoter and a nonfunctional immunoglobulin sequence, was used as a negative control; no CAT activity above basal level was detected in PHA/PMA-stimulated or nonstimulated S-LB-I cells (data not shown).
Cell-Type Specificity of GM-CSF Upstream Regulatory Sequences. To determine whether the 660-bp fragment is functional in non-T cells, +pCSFPI was transfected into PR, a human B-lymphoblastoid line (20) . No CAT activity was seen when transfected cells were stimulated with lipopolysaccharide, pokeweed mitogen, or PMA, using pSV2cat as a positive control for transfection (data not shown).
DISCUSSION
We report here the identification of a region in the GM-CSF gene that acts in cis to regulate its expression in activated T cells. Thus far, GM-CSF appears to be a cell-specific factor. The HTLV-transformed cell lines HuT 102 (27), J-LB-I, S-LB-I, Mo, and C10-MJ2 (7) all showed basal production of GM-CSF RNA. Stimulation by PHA/PMA increases the level by as much as 10-fold (ref. 7 and Fig. 1 ). The increase in GM-CSF mRNA is accompanied by increased GM-CSF protein in conditioned medium, as detected by radioimmunoassay (Fig. 2) .
Although peripheral blood lymphocytes showed no constitutive GM-CSF mRNA and a marked increase upon PHA/PMA stimulation (7), none of the currently available techniques efficiently transfect cloned DNA into primary T cells. We therefore chose to study GM-CSF induction in HTLV-transformed T-cell lines. The constructs we prepared contained 660 nucleotides 5' from the first ATG of the GM-CSF gene, linked in both orientations relative to the bacterial CAT gene. The production of CAT in the constructs was shown to depend on the GM-CSF promoter and regulatory sequences.
Our findings suggest that the 660-bp fragment contains cis-acting regulatory functions. Only stimulated cells HTLV-infected cells constitutively produce GM-CSF, no difference was detected in the background level of CAT activity between nonstimulated +pCSFPI-and -pCSFPItransfected S-LB-I cells. Thus, the constitutive production of GM-CSF in HTLV-infected cells may be mediated via sequences that are not in the 660-bp fragment. Our results also suggest that the GM-CSF regulatory sequence is cellspecific, since no CAT activity was detected in pokeweed mitogen-, endotoxin (lipopolysaccharide)-, or PMA-stimulated +pCSFPI-transfected Epstein-Barr virus-transformed B cells. Recent work has shown that endothelial cells and some types of fibroblasts can be induced by IL-1 or tumor necrosis factor to produce GM-CSF (28, 29) . It will be of interest to determine whether the sequences contained within the 660-bp fragment are involved in the expression of GM-CSF in these cell types.
We have also determined the transcription initiation ("cap") site of GM-CSF. The data indicate that transcription initiates at two different sites, nucleotides 28 (C) and 30 (G) from the putative "TATA box." This finding differs from that reported previously (30) for the human gene, where transcription initiates at nucleotides 23, 24, and 25 downstream from the TATA box. However, our finding correlates well with data obtained for the mouse gene (31) . Also, our S1 analysis showed no evidence for another GM-CSF mRNA, as reported by Gough and coworkers (31, 32) , that encodes a putative membrane-bound form of the protein.
It appears that GM-CSF expression is tightly regulated. It is possible to envision that T cells, when activated by physiological stimulators, produce cell-specific factors that trans-activate the GM-CSF gene via regulatory sequences situated within the 660-bp fragment. Comparison of the human and mouse GM-CSF showed sequences highly conserved in the region immediately upstream of the TATA box (30) . It is interesting that the reported decanucleotide lymphokine consensus sequence (31) 5' GRGRTTYCAY 3' (R = A or G; Y = C or T), found in the murine IL-2, IL-3, and GM-CSF genes and human IL-2 gene, also occurs in two regions of the 660-bp human GM-CSF fragment. The consensus sequence may account for coordinated expression of these genes in activated T cells. The sequence situated at nucleotides -336 to -357 shows 80% homology, whereas the sequence at -100 to -91 shows 100% homology to the putative regulatory sequence (Fig. 3) . It is possible that cell-specific factors produced during activation may act on these sequences to turn on GM-CSF production. Determination of the exact sequences with which T-cell-specific factors may interact will require the analysis of deletion and site-specific mutants of +pCSFPI. Genetics: Chan et al.
